GoConqr has a new look! Let us know what you think.

Sign up free

Quiz

MD7 Dissolution for drug release and therapeutic outcomes

Mer Scott 9 questions

Take the quiz

This quiz has question types that open in the usual player.

Questions in this quiz (9)

  1. 1Choose the incorrect statement.
    1. ASurface area is affected by the physiochemical property of particle size.
    2. BDiffusion is affected by molecular size and GIT fluid viscosity.
    3. CThickness of diffusion later is affected by GI motility.
    4. DSaturated concentration (Cs) is affected by the physiochemical properties crystalline
      structure and solubility, and the physiological variables pH, surfactants, bile salts, and food content.
    5. EBulk concentration of dissolved drug (C) is influenced by GI motility.
    6. FVolume of solvent (V) depends on volume of GIT fluids and secretions.
  2. 2Food ingestion is known to induce various physiological changes in the GI environment, such as higher levels of native [blank_start]surfactant[blank_end], [blank_start]small intestine[blank_end] secretions, [blank_start]larger volumes[blank_end] of fluids, and [blank_start]longer[blank_end] upper GI residence time.
    Poorly [blank_start]soluble[blank_end] compounds are especially prone to higher systemic exposure when given in the [blank_start]fed[blank_end] state, with the main effect being faster and more extensive dissolution under fed conditions. This is due to higher levels
    of native surfactant, presence of [blank_start]lipophilic meal components[blank_end] and the products of [blank_start]fat digestion[blank_end], as well as increased fluid and GIT residence time.
    1. Asurfactant
    2. Bsmall intestine
    3. Clarger volumes
    4. Dlonger
    5. Esoluble
    6. Ffed
    7. Glipophilic meal components
    8. Hfat digestion
  3. 3The in vivo dissolution behaviour of weak bases is additionally influenced by variations in [blank_start]upper GI pH[blank_end], making these drugs especially prone to food effects. Since the [blank_start]rate-determining step[blank_end] to the intestinal absorption of poorly soluble drugs is the [blank_start]dissolution[blank_end] in the gastrointestinal (GI) tract, [blank_start]postprandial[blank_end] changes in GI physiology, in addition to any specific [blank_start]interactions[blank_end] between drug and food, are expected to affect the pharmacokinetics and [blank_start]bioavailability[blank_end] of such drugs.
    1. Aupper GI pH
    2. Brate-determining step
    3. Cdissolution
    4. Dpostprandial
    5. Einteractions
    6. Fbioavailability
  4. 4Choose the correct statement.
    1. AIn the fasted state, motility in the upper GI tract is cyclical and passage is size independent.
    2. BIn the fed state, motility in the upper GI tract is cyclical and passage is size independent.
    3. CIn the fasted state, passage of bigger units may be delayed.
    4. DIn the fed state, passage of bigger units may be considerably accelerated.
  5. 5[blank_start]FaSSIF[blank_end] - Fasted state simulated intestinal fluid
    [blank_start]FeSSIF[blank_end] - Fed state simulated intestinal fluids
    [blank_start]FaSSGF[blank_end] - Fasted state simulated gastric fluid
    [blank_start]FeSSGF[blank_end] - Milk/buffer pH 5 combination simulate gastric conditions after a standard breakfast
    [blank_start]FeSSIF[blank_end] - V2 to simulate postprandial bile secretion, lipolysis products, increased buffer capacity and osmolality in upper SI after food intake
    1. AFaSSIF
    2. BFeSSIF
    3. CFaSSGF
    4. DFeSSGF
    5. EFeSSIF V-2
  6. 6Choose the incorrect statement
    1. ADisintegration testing is not a true predictor of how well the dosage form will release its active ingredient in vivo.
    2. BThe elucidation of the underlying mass transport mechanisms is not possible with disintegration testing.
    3. CThe elucidation of the underlying mass transport mechanisms is possible with dissolution testing.
  7. 7Pharmaceutical Equivalents - Drug products are considered pharmaceutical equivalents if they contain the [blank_start]same active ingredient[blank_end] in the [blank_start]same dosage form[blank_end] and are identical in [blank_start]strength or concentration[blank_end].
    Therapeutic Equivalents - Drug products which are [blank_start]pharmaceutical equivalents[blank_end] and are expected to have the same [blank_start]clinical[blank_end] effect and [blank_start]safety[blank_end] profile when administered to patients under conditions specified in the labelling.
    1. Asame active ingredient
    2. Bsame dosage form
    3. Cstrength or concentration
    4. Dpharmaceutical equivalents
    5. Eclinical
    6. Fsafety
  8. 8Bioequivalent Drug Products: This term describes [blank_start]pharmaceutically equivalent[blank_end] products that display comparable [blank_start]bioavailability[blank_end] when studied under similar experimental conditions.
    1. Apharmaceutically equivalent
    2. Bbioavailability
  9. 9Bioequivalence means that the active ingredient of 2 drug products have the same:
    1. Arate of absorption
    2. Bextent of absorption
    3. Crate and extent of absorption

Information

Description
PHCY211 (Medicines) Quiz on MD7 Dissolution for drug release and therapeutic outcomes, created by Mer Scott on 12/05/2018.
Author
Mer Scott
Language
English
Views
10
Rating
No ratings yet
Rate this quiz
Rate this quiz

Feedback

What is it about?

What do you think of the new look?

How do you like it?